| TAR DNA-Binding Protein 43 (TDP-43) | |
|---|---|
| Gene | TARDBP |
| UniProt | Q13148 |
| PDB | 2N4P, 5E1O, 6N3T |
| Mol. Weight | 44.7 kDa (full-length), 43 kDa (cleaved) |
| Localization | Nucleus, cytoplasm |
| Family | Heterogeneous nuclear ribonucleoprotein (hnRNP) family |
| Diseases | Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer's Disease |
Tar Dna Binding Protein 43 (Tdp 43) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TAR DNA-Binding Protein 43 (TDP-43) is a 414-amino acid nuclear protein encoded by the TARDBP gene that plays a critical role in RNA metabolism and has emerged as a central player in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)[1]. TDP-43 is the major constituent of cytoplasmic inclusions found in approximately 95% of ALS cases and 50% of FTD cases, making it one of the most important pathological proteins in neurodegenerative disease[2].
TDP-43 contains several distinct structural domains:
The N-terminal domain contains a nuclear localization signal (NLS) and is involved in protein-protein interactions. This domain facilitates the formation of TDP-43 dimers and trimers.
RRM1 is responsible for binding to single-stranded DNA and RNA. It has a strong preference for UG-rich sequences and can bind to TAR DNA elements (hence the name TARDBP).
RRM2 works in concert with RRM1 for RNA binding and contributes to the protein's ability to regulate alternative splicing.
The C-terminal region is intrinsically disordered and contains a glycine-rich domain and a prion-like glutamine/asparagine (Q/N)-rich domain. This region is prone to aggregation and contains most disease-causing mutations[3].
TDP-43 is a multifunctional RNA-binding protein involved in:
TDP-43 normally shuttles between the nucleus and cytoplasm, but nuclear import is mediated by importin-α/β and the NLS, while export is facilitated by Exportin-1 (CRM1)[4].
TDP-43 aggregation is a hallmark of ALS and FTD. The pathological process involves:
Over 50 mutations in TARDBP have been linked to ALS/FTD, predominantly in the C-terminal region:
ASO targeting TARDBP mRNA to reduce mutant protein expression is in pre-clinical development.
Viral vector delivery of wild-type TDP-43 or anti-aggregation proteins is being explored.
The study of Tar Dna Binding Protein 43 (Tdp 43) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Science. 2006;314(5796):130-133. DOI:10.1126/science.1134108 ↩︎
Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602-611. DOI:10.1016/j.bbrc.2006.10.093 ↩︎
Da Cruz S, Cleveland DW. Disrupted nuclear import and export in TDP-43: a new therapeutic target? Neuron. 2011;71(5):761-763. DOI:10.1016/j.neuron.2011.08.015 ↩︎
Nishimura AL, Zupunski V, Troakes C, et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation in aged and expanded ATXN2 poly(Q) tracts. Brain. 2010;133(Pt 10):2990-3002. DOI:10.1093/brain/awq227 ↩︎
Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38-50. DOI:10.1038/nrn3120 ↩︎